Novo Nordisk sues Eli Lilly over "maliciously and deceptively false" GLP-1 ads
CBS News • • business
Key Points:
- Novo Nordisk has sued Eli Lilly, accusing the company of false advertising by claiming its GLP-1 drugs, Zepbound and Mounjaro, are superior to Novo's Wegovy and Ozempic for weight loss and Type 2 diabetes treatment.
- The lawsuit alleges Eli Lilly used outdated clinical trial data, comparing its highest drug doses to lower doses of Novo Nordisk's medicines, misleading consumers about the drugs' effectiveness.
- Novo Nordisk states that the FDA has approved newer, more effective doses of its drugs, but Eli Lilly's ads failed to reference this updated dosage information accurately.
- Eli Lilly defends its advertising as truthful, transparent, and based on direct scientific evidence, and says it will vigorously defend against the lawsuit.
- The lawsuit also claims that Eli Lilly's acknowledgment of higher Wegovy doses in its ads is minimal and unclear, described as "ambiguous" and "virtually invisible."
